

1 **Impact of the COVID-19 pandemic on breast cancer screening indicators**  
2 **in a Spanish population-based program: a cohort study.**

3

4 **Authors**

5 Guillermo Bosch, MD <sup>1,2</sup>; Margarita Posso, MD, PhD<sup>1,3\*</sup>; Javier Louro, PhD<sup>1,3</sup>; Marta  
6 Roman, PhD<sup>1,3</sup>; Miquel Porta, MD, PhD<sup>4,5,6</sup>; Xavier Castells, MD, PhD<sup>1,3,4</sup>; Francesc Macià,  
7 MD<sup>1,3</sup>.

8

9 **Affiliations**

10 <sup>1</sup> Department of Epidemiology and Evaluation, IMIM (Hospital del Mar Medical Research  
11 Institute), Barcelona, Spain

12 <sup>2</sup> Preventive Medicine and Public Health Training Unit PSMar-ASPB-UPF, Barcelona, Spain

13 <sup>3</sup> Research Network on Chronicity, Primary Care and Health Promotion (RICAPPS),  
14 Barcelona, Spain

15 <sup>4</sup> Universitat Autònoma de Barcelona, Barcelona, Catalonia, Spain

16 <sup>5</sup> Hospital del Mar Institute of Medical Research (IMIM PSMar), Barcelona, Catalonia, Spain

17 <sup>6</sup> Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP),  
18 Madrid, Spain

19

20

21 **Institution**

22 Department of Epidemiology and Evaluation, IMIM (Hospital del Mar Medical Research  
23 Institute), Passeig Marítim 25-29, Barcelona 08003, Spain

24

25 **Corresponding author**

26 Margarita Posso, MD, PhD

27 Department of Epidemiology and Evaluation, IMIM (Hospital del Mar Medical Research  
28 Institute), Passeig Marítim 25-29, 08003, Barcelona, Spain.

29 E-mail: [mposso@parcdesalutmar.cat](mailto:mposso@parcdesalutmar.cat)

30 Telephone number: +34 932483929

31

**NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

1 **Abstract**

2 **Background:**

3 To assess the effect of the COVID-19 pandemic on performance indicators in the population-  
4 based breast cancer screening program of Parc de Salut Mar (PSMAR), Barcelona, Spain.

5 **Methods:**

6 We conducted a before-and-after, quasi-experimental study to evaluate participation, recall,  
7 false-positives, cancer detection rate, and cancer characteristics in our screening population  
8 from March 2020 to March 2021 compared with the four previous rounds (2012-2019). Using  
9 independent logistic regression models, we estimated the adjusted odds ratios (aOR) of each  
10 of the performance indicators for the COVID-19 period, controlling by type of screening  
11 (prevalent or incident), socioeconomic index, family history of breast cancer, and menopausal  
12 status. We analyzed 144,779 observations from 47,571 women.

13 **Results**

14 During the COVID-19 period, the odds of participation were 11% lower in first-time invitees  
15 (aOR=0.89[95%CI=0.84-0.96]) and in those who had previously participated regularly and  
16 irregularly (aOR=0.65 [95%CI=0.61-0.69] and aOR=0.93 [95%CI=0.85-1.03], respectively).  
17 Participation showed a modest increase in women not attending any of the previous rounds  
18 (aOR=1.07 [95%CI=0.99-1.17]). The recall rate slightly decreased in both prevalent and  
19 incident screening (aOR=0.89 [95%CI=0.78-1.01] and aOR=0.89 [95%CI=0.79-1.00],  
20 respectively). No significant differences were observed in false-positives (prevalent -  
21 aOR=1.07 [95%CI=0.92-1.24] and incident screening -aOR=0.94 [95%CI=0.82-1.08]),  
22 cancer detection rate (aOR=0.91 [95%CI=0.69-1.18]), or cancer stages.

23 **Conclusions:**

24 The COVID-19 pandemic negatively affected screening attendance, especially in previous  
25 participants and newcomers. We found no marked differences in recall, false-positives, or  
26 cancer detection, indicating the program's resilience. There is a need for further evaluations  
27 of interval cancers and potential diagnostic delays.

28 **Keywords:** Early detection of cancer; breast neoplasm; non-randomized controlled trials;  
29 quality indicators, COVID-19.

30 **Abbreviations:**

31 **aOR:** adjusted odds ratio

32 **BHA:** basic Health Area

33 **CI:** Confidence interval

34 **PSMAR:** Parc de Salut Mar

35

36

## 1 Introduction

2 In numerous health systems cancer screening programs were among the first activities  
3 interrupted by the COVID-19 pandemic after its irruption in early 2020. As reported in a  
4 survey by the International Cancer Screening Network, 97% of participating settings reported  
5 that COVID-19 had adversely impacted their screening programs, while 90% partially  
6 suspended their activity (1,2). Even in countries with notable success in containing the  
7 pandemic, like Taiwan, the population attending screening decreased during the first half of  
8 2020 (3).

9 In Europe, breast cancer screening is mostly provided through organized programs offering  
10 routine mammography examination to women aged from 45-50 to 69-74 years. The programs  
11 follow the guidelines of the European Commission Initiative for Breast Cancer Screening and  
12 Diagnosis (4). These guidelines recommend an evidence-based set of performance indicators  
13 to evaluate the quality of the screening provision (5). The suspension of these programs led to  
14 a reduction in cancer diagnoses. For instance, in the Netherlands and Austria, the number of  
15 breast cancer diagnoses decreased substantially and remained lower than expected until  
16 screening was rebooted (6,7), while in Italy, between January and May 2020, 53% fewer  
17 screens were performed, with a median delay of 2.7-month for screening mammograms (8).

18 Currently, the evidence of the effect of the COVID-19 pandemic on breast cancer screening  
19 performance indicators has been mostly provided by simulation models and longitudinal  
20 studies are scarce. In Canada, Yong et al. used a mathematical model to estimate that a three-  
21 month halt would have led to 664,000 fewer screening mammograms than expected, based on  
22 nationwide data from the previous year. It would also have decreased breast cancer diagnoses  
23 by 7% in 2020 and caused 110 excess deaths by 2029 (9). Similar models in Italy reported  
24 that 8,125 breast cancer diagnoses were expected to be delayed due to a three-month  
25 interruption of screening programs, representing 25% of the 32,500 yearly screening  
26 diagnoses nationwide (10).

27 Spain was one of the first and most affected countries in Europe during the spring of 2020  
28 (11,12). On March 14th, a general lockdown was enforced, and breast cancer screening was  
29 interrupted (13). Restrictive measures were slowly withdrawn during the following three  
30 months until June 21<sup>st</sup>, when the lockdown ended (14). To reintroduce the screening  
31 programs as soon as possible while continuing to control the risk of COVID-19 transmission,  
32 mammography centers established new safety guidelines (15,16).

33 Given the scarcity of longitudinal studies, we used a before-and-after design including data  
34 from a population-based program from 2012 to 2021. We aimed to assess the impact of the  
35 COVID-19 pandemic on the performance indicators of the program of Parc de Salut Mar  
36 (PSMAR) of Barcelona, Catalonia, Spain.

37

## 38 Methods

### 39 Study design

1 In this before-and-after study, we compared the population-based breast cancer screening  
2 indicators obtained in a single population before and after the COVID-19 pandemic.

### 3 **Study population**

4 In Spain, publicly funded mammographic screening for breast cancer is offered every two  
5 years to women aged 50 to 69 years (17). The screening examination at PSMAR consists of  
6 both a mediolateral oblique and a craniocaudal digital (two-dimensional) mammographic  
7 view of each breast. Two independent radiologists with extensive experience perform blinded  
8 double reading of mammograms. Disagreements are resolved by a third senior radiologist  
9 (18). The program covers the population of four districts of the city of Barcelona, with  
10 around 620,000 inhabitants. Until the current pandemic, screening invitations were sent by  
11 postal mail with a pre-scheduled mammography appointment. Since June 2020, previous  
12 participants have also received a reminder by telephone.

13 Invitations are issued during the two-year duration of each screening round according to the  
14 geographical criteria set by Basic Health Areas (BHA), which are the basic territorial  
15 healthcare units of the city. In this analysis, we used data from 10 out of the 25 BHA covered  
16 by the PSMAR breast cancer screening program. The 10 BHA selected were those affected  
17 by the interruption and delay of the screening program during the first year of the pandemic,  
18 invitations for women from such BHA should have been sent out between March 2020 and  
19 March 2021.

20 For this study, the pre-COVID-19 period started in March 2012, ended in March 2019, and  
21 was divided into four pre-COVID-19 rounds of two years each. The post-COVID-19 period,  
22 therefore, went from March 2020 to March 2021, and included one screening round. We  
23 extended the follow-up until September 2021 to include the process of cancer diagnosis for  
24 women attending screening in the post-COVID round.

25 We obtained a total of 144,779 observations, from 47,571 eligible women throughout the 10  
26 years of study. Each of these observations represented an invitation to the screening program.  
27 In our study population, age group, socioeconomic status, and type of screening round were  
28 statistically different in the post- and pre-COVID-19 periods, (Table 1). The percentage of  
29 invited women living in high-income areas decreased slightly (-1.03%) as did that of women  
30 younger than 55 years (-1.83%). The distribution of the type of screening of invited women  
31 also changed, with a higher percentage of invitations for prevalent screening (+1.69%),  
32 especially first-time invitees (+2.90%).

33

**Table 1.** Baseline characteristics of women invited to the PSMAR breast cancer screening program in the BHA (Basic Health Areas) affected by the COVID-19 pandemic in the area of reference of Parc de Salut Mar (PSMAR), in Barcelona, Spain in the period 2012-2021 by screening round.

		Pre-COVID 4		Pre-COVID 3		Pre-COVID 2		Pre-COVID 1		Pre-COVID Total		Post-COVID +1		Difference	
		Round		Round		Round		Round		Round		Round		post-pre	Dif
		(2012-2013)		(2014-2015)		(2016-2017)		(2018-2019)		(2012-2019)		(2020-2021)			
		n	%	n	%	n	%	n	%	n	%	n	%		
<b>Age Group</b>	50-54	9,103	31.79%	9,495	32.55%	9,451	32.25%	9,013	31.41%	37,062	32.00%	8,743	30.17%	-1.83%	^
	55-59	7,153	24.98%	7,345	25.18%	7,569	25.83%	7,631	26.59%	29,698	25.65%	7,899	27.26%	1.61%	^
	60-64	6,687	23.36%	6,573	22.53%	6,692	22.84%	6,666	23.23%	26,618	22.99%	6,831	23.57%	0.59%	^
	65-70	5,688	19.87%	5,756	19.73%	5,593	19.09%	5,387	18.77%	22,424	19.36%	5,504	18.99%	-0.37%	
<b>Socio-economic index level</b>	Low	4,458	15.57%	4,472	15.33%	4,371	14.92%	4,371	15.23%	17,672	15.26%	4,536	15.65%	0.39%	
	Middle-Low	2,303	8.04%	2,356	8.08%	2,329	7.95%	2,338	8.15%	9,326	8.05%	2,506	8.65%	0.59%	^
	Middle-High	15,209	53.12%	15,668	53.71%	15,864	54.13%	15,557	54.21%	62,298	53.80%	15,600	53.84%	0.04%	
	High	6,661	23.26%	6,673	22.88%	6,741	23.00%	6,431	22.41%	26,506	22.89%	6,335	21.86%	-1.03%	^
<b>Type of screening</b>															
<b>Prevalent</b>	First-invitation	4,409	15.40%	4,571	15.67%	4,271	14.57%	3,831	13.35%	17,082	14.75%	5,114	17.65%	2.90%	^
	Previous non participant	8,497	29.68%	8,639	29.62%	9,049	30.88%	9,012	31.40%	35,197	30.39%	8,456	29.18%	-1.21%	^
	Total	12,906	45.08%	13,210	45.29%	13,320	45.45%	12,843	44.75%	52,279	45.15%	13,570	46.83%	1.69%	
<b>Incident</b>	Regular participant	13,410	46.84%	13,478	46.21%	13,495	46.05%	13,390	46.66%	53,773	46.44%	13,070	45.10%	-1.33%	^
	Irregular participant	2,315	8.09%	2,481	8.51%	2,490	8.50%	2,464	8.59%	9,750	8.42%	2,337	8.07%	-0.35%	
	Total	15,725	54.92%	15,959	54.71%	15,985	54.55%	15,854	55.25%	63,523	54.85%	15,407	53.17%	-1.69%	
<b>TOTAL</b>		28,631	100.00%	29,169	100.00%	29,305	100.00%	28,697	100.00%	115,802	100.00%	28,977	100.00%		

Pre-covid totals calculated as the sum of the 4 pre-COVID screening rounds. Percentages show the distribution for the columns of each variable. P-values obtained with Chi-square test comparing the total pre-COVID and post-COVID proportions <0.001 for all variables. Dif='^' indicates a statistically significant difference of p<0.05 between columns of the respective category.

## 1 **Data sources**

2 All data from women eligible for screening was obtained from the management database of  
3 the program, which is updated yearly with the screening status and baseline characteristics of  
4 both participants and non-participants over the years. We completed the information on  
5 cancer histology and tumor stages with data the clinical and pathological records.

6 Each screening invitation was considered an independent measurement. All measurements  
7 were pseudo-anonymized by using an individual ID for each woman while removing all  
8 personal data. Therefore, although multiple measurements per woman could be obtained from  
9 invitations in different rounds, all of them shared the same pseudo-anonymized ID.

## 10 **Outcomes**

11 From the screening database of the program, we obtained the indicators on the selected BHA  
12 for the 2020-21 screening round, which, as mentioned, was categorized as the post-COVID-  
13 19 period. We compared the post-COVID-19 indicators with those from the four previous  
14 screening rounds of the same BHA, categorized as the pre-COVID-19 period. We used four  
15 main indicators of the program: participation, recall, false-positives, and detection rate. In  
16 addition, we also compared the following characteristics of the detected tumors, histology  
17 (invasive vs. in situ), tumor size, lymphatic invasion, the presence of metastases, and stage at  
18 diagnosis.

19 Participation was measured as the percentage of women invited for screening who underwent  
20 mammography in the corresponding round. Invited women were those fulfilling the selection  
21 criteria (age 50 to 69 years, residence in the selected BHA) and who did not meet of the  
22 exclusion criteria of the program. The main exclusion criteria were a change of address  
23 outside the geographic area of the program, previous breast cancer, high hereditary risk of  
24 breast cancer and errors in identification or personal data.

25 The other three outcomes were analyzed using only the screening participants. The recall rate  
26 was estimated as the percentage of participants who were advised to undergo further  
27 assessment to rule out malignancy, whether non-invasive or invasive (ultrasound,  
28 tomosynthesis, contrast-enhanced mammography, biopsy, and/or others). False positives  
29 were estimated based on the percentage of women who underwent additional non-invasive or  
30 invasive assessments but who did not have a diagnosis of cancer after completion of  
31 additional examinations. The detection rate was the number of breast cancers detected at  
32 screening per 1000 participants. We calculated this rate, stratifying by type of breast cancer  
33 histology (i.e., the invasive or in situ cancer detection rate).

34 We stratified all the invitations by type of screening between prevalent or incident screening.  
35 Prevalent screening refers to the process of inviting women who have never participated in  
36 screening, while incident screening refers to inviting previous participants. In terms of  
37 prevalent screening, we differentiated between first-time invitees, and non-participants,  
38 referring to previously invited women who had never participated. For incident screening, we  
39 differentiated between previous participants who had participated in the previous round  
40 (regular participants) and those not participating in the last round (irregular participants).

1 We categorized women according to their age at the time of invitation in four groups: 50-54,  
2 55-59, 60-64, and 65-70 years old. Socio-economic status was estimated with a compound  
3 socioeconomic index, created by the Government of Catalonia to assign resources to primary  
4 health care, based on the index of each BHA (19). Each woman was assigned the  
5 socioeconomic index of the BHA where she was living. Higher values denote a lower  
6 socioeconomic level.

7 We evaluated clinical variables such as menopausal status and family history of breast  
8 cancer. Breast cancer histology differentiates between in situ and invasive tumors. According  
9 to the TNM Breast Cancer 8<sup>th</sup> Edition classification (20), tumor size was measured in  
10 millimeters, lymphatic invasion as the extension of malignant cells, metastasis as its presence  
11 or absence, and stage at diagnosis as I, II, III, and IV TNM categories. We used the pathology  
12 (p)TNM preferably, and only used the clinical (c)TNM for women with neoadjuvant  
13 treatment (21). Other epidemiological and clinical variables such as educational level or  
14 history of hormone replacement therapy were not included in the analyses due to a high  
15 percentage of missing values (>10%).

## 16 **Statistical analysis**

17 We first compared the characteristics of the invited population among the different screening  
18 rounds to describe variations in their distribution. We evaluated differences in the categories  
19 using the chi-square test or the exact Fisher test when appropriate.

20 Then, we created independent logistic regression models to estimate adjusted odds ratios  
21 (aOR) of each of the performance indicators and their corresponding 95% confidence  
22 intervals (95% CI) for the COVID-19 period, adjusting by the clinically relevant variables.

23 For participation, we included the following variables in the model: type of screening round  
24 (prevalent vs. incident), age group, and socio-economic index. We found a strong interaction  
25 between COVID-19 and the type of screening round. Therefore, we created a new variable,  
26 which represented this interaction. Hence, the final models for participation differentiated  
27 four screening groups (prevalent-first-time invitee, prevalent-previous nonparticipant,  
28 incident-regular participant, and incident-irregular participant). We obtained crude results and  
29 adjusted by age and socioeconomic index.

30 We created three additional models, including only participants, to assess the impact of  
31 COVID-19 on the other main indicators of the screening program: recall, false-positives, and  
32 the screen-detected cancer rate (invasive or in situ). These models were adjusted for age  
33 group, menopausal status, and breast cancer family history.

34 Finally, we compared the stage at diagnosis and the remaining cancer characteristics (size,  
35 lymph node invasion, and metastasis invasion) of cases detected in the screening program in  
36 the pre- and post-COVID-19 periods.

37 Statistical tests were two-sided and all p-values lower than .05 were considered statistically  
38 significant.

1 SPSS version 25 software was used for the creation and validation of the database and  
2 recodification of variables, while statistical software R version 3.5.0 (Development Core  
3 Team, 2014) was used for the logistic regression models.

#### 4 **Ethical aspects**

5 The study guaranteed Spain's legal regulations on data confidentiality (law 15/99 of  
6 December 13 on the protection of personal data). Due to the retrospective nature of the study  
7 and the absence of direct contact with women, which did not affect their relationship with the  
8 program, informed consent was waived by the Ethics Committee of PSMAR, which approved  
9 the study (reg.2021/9866).


#### 10 **Results**

11 The participation in the program was affected differently depending on the type of screening.  
12 The odds of participating during the post-COVID-19 period were 10% lower (aOR=0.90 95%  
13 CI-, 0.84-0.96) for the group of first-time invitees than during the pre-COVID-19 period. The  
14 aOR was 1.07 (95% CI, 0.99-1.17) for the previous non-participant group between the post-  
15 and pre-COVID-19 periods. For the group of women who had participated in the previous  
16 round (regular participants), the aOR of participation was 0.65 (95% CI 0.61-0.69), and for  
17 those not participating in the last round (irregular participants), the aOR was 0.93 (95% CI  
18 0.85-1.03) (Figure 1).

19



Figure 1. Adjusted Odds Ratios of Pre-post COVID-19 models for participation.



\*aOR: adjusted odds ratio of participating for post-COVID round vs pre-COVID rounds  
 \*aOR adjusted by age, socioeconomic index

1 We also found statistically significant differences in the distribution of baseline  
2 characteristics of participants during the post-COVID-19 round compared with the mean  
3 distributions of the pre-COVID-19 period (Table 2). The percentage of participants younger  
4 than 55 years decreased (-1.64%) but the percentage aged between 55 and 59 years increased  
5 (+1.73%). The percentage of participants from high socioeconomic level areas slightly  
6 decreased (-0.62%). The biggest changes in the distribution of participants were seen between  
7 types of screening, with a substantial decrease among participants in the incident screening  
8 group (-2.39%) and an increase in the percentage of prevalent screening, especially first-time  
9 invitees (+1.96%). The percentage of participants with a family history of breast cancer  
10 increased by 2.53%.

11

**Table 2.** Baseline characteristics of participants of the PSMAR breast cancer screening program in the BHA affected by the COVID-19 pandemic in the area of reference of Parc de Salut Mar (PSMAR), in Barcelona, Spain in the period 2012-2021 by screening round.


		Pre-COVID 4 Round (2012-2013)		Pre-COVID 3 Round (2014-2015)		Pre-COVID 2 Round (2016-2017)		Pre-COVID 1 Round (2018-2019)		Pre-COVID Total (2012-2019)		Post-COVID +1 Round (2020-2021)		Difference post-pre Dif	
		n	%	n	%	n	%	n	%	n	%	n	%		
<b>Age Group</b>	50-54	4,550	29.22%	4,596	29.50%	4,546	29.39%	4,434	28.56%	18,126	29.17%	4,073	27.53%	-1.64%	^
	55-59	3,912	25.12%	3,901	25.04%	3,985	25.77%	4,089	26.34%	15,887	25.57%	4,038	27.29%	1.73%	^
	60-64	3,784	24.30%	3,729	23.94%	3,710	23.99%	3,780	24.35%	15,003	24.14%	3,664	24.77%	0.62%	
	65-70	3,325	21.35%	3,352	21.52%	3,225	20.85%	3,220	20.74%	13,122	21.12%	3,020	20.41%	-0.71%	
<b>Socio-economic index level</b>	Low	3,282	21.08%	3,223	20.69%	3,201	20.70%	3,226	20.78%	12,932	20.81%	3,065	20.72%	-0.10%	
	Middle-Low	1,603	10.29%	1,612	10.35%	1,620	10.47%	1,630	10.50%	6,465	10.40%	1,586	10.72%	0.31%	
	Middle-High	8,363	53.71%	8,537	54.80%	8,508	55.01%	8,626	55.57%	34,034	54.77%	8,164	55.18%	0.41%	
	High	2,323	14.92%	2,206	14.16%	2,137	13.82%	2,041	13.15%	8,707	14.01%	1,981	13.39%	-0.62%	^
<b>Type of screening Prevalent</b>	First-invitation	2,058	13.22%	1,957	12.56%	1,876	12.13%	1,850	11.92%	7,741	12.46%	2,133	14.42%	1.96%	^
	Previous non participant	812	5.21%	771	4.95%	750	4.85%	763	4.92%	3,096	4.98%	802	5.42%	0.44%	^
	Total	2,870	18.43%	2,728	17.51%	2,626	16.98%	2,613	16.83%	10,837	17.44%	2,935	19.84%	2.40%	
<b>Incident</b>	Regular participant	12,003	77.09%	12,116	77.78%	12,095	78.20%	12,098	77.94%	48,312	77.75%	11,166	75.47%	-2.28%	^
	Irregular participant	698	4.48%	734	4.71%	745	4.82%	812	5.23%	2,989	4.81%	695	4.70%	-0.11%	
	Total	12,701	81.57%	12,850	82.49%	12,840	83.02%	12,910	83.17%	51,301	82.56%	11,861	80.17%	-2.39%	
<b>Menopause</b>	Yes	12,069	77.52%	12,358	79.34%	12,212	78.98%	12,267	79.03%	48,906	78.71%	11,683	78.97%	-0.18%	
	No	1,986	12.76%	1,973	12.67%	2,095	13.54%	2,106	13.56%	8,160	13.13%	1,978	13.37%	0.18%	
	Unknown	1,516	9.74%	1,247	8.00%	1,159	7.49%	1,150	7.41%	5,072	8.16%	1,134	7.66%		
<b>Breast cancer family history</b>	Yes	2,755	17.69%	2,915	18.71%	3,039	19.65%	3,213	20.70%	11,922	19.19%	3,207	21.67%	2.53%	^
	No	12,792	82.15%	12,633	81.10%	12,390	80.11%	12,265	79.01%	50,080	80.59%	11,532	77.94%	-2.53%	^
	Unknown	24	0.15%	30	0.19%	37	0.24%	45	0.29%	136	0.22%	56	0.38%		
<b>Education level</b>	Primary or lower	4,641	29.81%	4,024	25.83%	3,370	21.79%	2,776	17.88%	14,811	23.84%	2,032	13.73%	-11.78%	^
	Middle level	6,156	39.54%	6,367	40.87%	6,575	42.51%	7,371	47.48%	26,469	42.60%	7,941	53.67%	14.31%	^
	University	2,405	15.45%	2,658	17.06%	2,930	18.94%	2,777	17.89%	10,770	17.33%	2,213	14.96%	-2.53%	^
	Unknown	2,369	15.21%	2,529	16.23%	2,591	16.75%	2,599	16.74%	10,088	16.23%	2,609	17.63%		
<b>Total</b>		15,571	100.00%	15,578	100.00%	15,466	100.00%	15,523	100.00%	62,138	100.00%	14,795	100.00%		

Pre-covid totals calculated as the sum of the 4 pre-COVID screening rounds. Percentages show the distribution in the columns of each variable. P-values obtained with Chi-square test comparing the total pre-COVID and post-COVID proportions. Dif="^" indicates a statistically significant difference of  $p < 0.05$  between columns of the respective category.

1 The analysis of recall revealed modest decreases of 11% in the likelihood of being advised to  
2 undergo additional testing the post-COVID-19 period in both the prevalent and the incident  
3 screening groups (aOR 0.89 [95% CI 0.78-1.01], and aOR 0.89 [95% CI 0.79-1.00]). The  
4 aOR of a false positive result for prevalent and incident screening was 1.07 (95% CI, 0.92-  
5 1.24) and 0.94 (95% CI, 0.82-1.08), respectively. The aOR of cancer detection in the post-  
6 COVID vs the pre-COVID-19 period was 1.01 (95% CI 0.56-1.71) and 0.87 (95% CI 0.63-  
7 1.17) in the prevalent and incident screening groups, respectively (Figure 2).

8

Figure 2. Adjusted Odds Ratios of Pre-post COVID-19 models for recall, false positives, and cancer detection in participants.



\*aOR: adjusted odds ratio of having the event for postCOVID round vs preCOVID rounds

\*aOR adjusted by age, menopause status, family history of breast cancer.


1 When differentiating between cancer histology, we found no statistically significant  
2 reductions in the odds of being diagnosed with a carcinoma in situ (aOR 0.74 [95% CI 0.32-  
3 1.47]) or an invasive tumor (aOR 0.95 [95% CI 0.70-1.26]), whereas the aOR for all tumors  
4 was 0.91 [95% CI 0.69-1.18] (Figure 3). Finally, we observed no statistically significant  
5 differences in the distribution of the tumor size, lymphatic invasion, the presence of  
6 metastasis or stage at diagnosis between the pre- and post-COVID-19 periods. A statistically  
7 non-significant decrease of 4.47% in in-situ tumors, and a non-significant increase of 4.95%  
8 in stages I were noted (Table 3).

9 All crude results did not significantly differ from those adjusted (supplementary file 1).

10

Figure 3. Adjusted Odds Ratios of Pre-post COVID-19 models for cancer detection according to histology.

Cancer detection	Pre-COVID19	Post-COVID19	aOR*
	No. of cancers/total No. (%)		
In situ	50 / 62,138 (0.80‰)	8 / 14,796 (0.54‰)	0.74 (0.32 - 1.47)
Invasive	259 / 62,138 (4.20‰)	60 / 14,796 (4.06‰)	0.95 (0.70 - 1.26)
Overall	330 / 62,138 (5.31‰)	71 / 14,796 (4.79‰)	0.91 (0.69 - 1.18)



\*aOR: adjusted odds ratio of having the event for postCOVID round vs preCOVID rounds

\*aOR adjusted by by age, menopause status, family history of breast cancer.

**Table 3.** Staging of cancers detected in each screening round in the BHA affected by the COVID-19 pandemic in the area of reference of Parc de Salut Mar (PSMAR), in Barcelona, Spain in the period 2012-2021 by screening round.

		Pre-COVID Total (2012-2019)		Post-COVID +1 Round (2020-2021)		Difference post-pre
		n	%	n	%	
<b>T</b>	In Situ	51	15.45%	8	11.27%	-4.76%
	1	210	63.64%	47	66.20%	0.48%
	2	43	13.03%	13	18.31%	4.92%
	3	8	2.42%	2	2.82%	0.32%
	4	3	0.91%	0	0.00%	-0.95%
	Unknown	15	4.55%	1	1.41%	
<b>N</b>	0	254	76.97%	58	81.69%	1.97%
	1	47	14.24%	10	14.08%	-0.68%
	2	8	2.42%	2	2.82%	0.31%
	3	5	1.52%	0	0.00%	-1.59%
	Unknown	16	4.85%	1	1.41%	
<b>M</b>	0	307	93.03%	68	95.77%	0.97%
	1	3	0.91%	0	0.00%	-0.97%
	Unknown	20	6.06%	3	4.23%	
<b>Clinical Stage</b>	In situ	50	15.15%	8	11.27%	-4.47%
	I	175	53.03%	42	59.15%	4.95%
	II	62	18.79%	16	22.54%	3.40%
	III	18	5.45%	2	2.82%	-2.90%
	IV	3	0.91%	0	0.00%	-0.97%
	Unknown	22	6.67%	3	4.23%	
<b>TOTAL</b>		330	100.00%	71	100.00%	

Pre-COVID totals calculated as the sum of the four pre-COVID rounds. Difference post-pre calculated comparing the post and the total pre-COVID percentages. Percentages show the distribution in the columns of each variable. P-value of the distribution of each variable calculated with the exact test of Fisher. Dif='^' indicates a significant difference of  $p > 0.05$  between columns of the respective category



## 1 Discussion

2 In this longitudinal study, we found that the pandemic reduced participation, but that this  
3 impact differed according to each woman's history of participation. Although attendance was  
4 lower during the pandemic period, we found no significant differences in other performance  
5 indicators, such as the frequency of recall for additional tests after mammography, the  
6 percentage of false-positive results, or the cancer detection rate.

7 Women who became eligible for invitation to our population-based screening program for the  
8 first time in the post-COVID-19 period were significantly less likely to participate during the  
9 pandemic. This effect was also noted, and in a much higher degree, in women who had  
10 participated in the previous round. A reduction in participation, although non-statistically  
11 significant, was also seen in women with previous irregular participation. Even though we  
12 could not identify the exact reasons behind the lower participation, we hypothesize that  
13 possible factors could be general insecurity related to attending hospitals, governmental  
14 restrictions of movement, fear of COVID-19 infection, and other uncertainties about the  
15 safety of participating in the screening process. This hypothesis is supported by data from a  
16 Danish study reporting that two of the reasons for postponing or canceling mammography  
17 appointments during the first year of the pandemic were fear and lack of clear guidance on  
18 the safety of screening (22).

19 Women who had been previously invited but had never attended our screening invitation  
20 seemed to participate slightly more during the pandemic period, although this difference was  
21 not statistically significant. The increase in participation was not expected since this group of  
22 women is that with the lowest participation in our setting (23). However, this change could be  
23 explained by a plausible modification in attitudes to screening with a possible increase in  
24 health-consciousness promoted by the pandemic, prompting women who had never been  
25 interested in screening to participate for the first time.

26 Overall, our findings on participation adjusted by age and socioeconomic status showed that  
27 the effect of the pandemic on screening attendance depended on each woman's previous  
28 participation status. Although the aim of our study was not to evaluate the factors associated  
29 with participation, we found a lower representation of high-income women in the post-  
30 COVID-19 period. This observation could be related to the pandemic situation, and should be  
31 confirmed, and is contrary to previous evidence. Nevertheless, it may well reflect a real  
32 phenomenon. A systematic review of studies conducted before the pandemic reported lower  
33 participation in low-income groups, immigrants, non-homeowners, and women with a  
34 previous false-positive result (24). Furthermore, studies recently published in the US have  
35 reported a decrease in participation, especially in underserved ethnic groups, with lower  
36 socioeconomic status, lack of insurance and longer travel time (25,26). Monitoring this  
37 information would allow programs to make efforts to promote participation among women at  
38 higher risk of not participating, especially under disruptive situations.

39 Despite the lower participation, the remaining performance indicators in our program did not  
40 seem to be significantly affected by the pandemic. Our results showed a non-statistically  
41 significant reduction in the recall rates of both prevalent and incident screening. These

1 findings could be due to the increased workload caused by COVID-19 patients at our and  
2 many other hospitals, which strongly affected the radiology department in 2020 (27).  
3 Regarding the frequency of false positives, we found no significant variation due to the  
4 pandemic, suggesting that the diagnostic accuracy of the radiologists reading the  
5 mammograms was not materially affected. Similar pieces of evidence of the resilience of our  
6 public health-care system have been recently reported in other hospitals in Barcelona (28),  
7 suggesting the strong resilience of health professionals working in critical situations. The  
8 COVID-19 pandemic has proved to be a stress test for health care systems around the world  
9 and the main elements related to highly effective responses have been associated with  
10 adaptation of health systems' capacity, reduction of vulnerability, preservation of health care  
11 functions and resources, and activation of comprehensive responses (29).

12 We found no differences in the odds of screen-detected cancer for either prevalent or incident  
13 screenings when comparing the pre- and post-COVID-19 periods. In contrast to our statistical  
14 approach to estimate the cancer detection as the number of tumors per 1,000 participants,  
15 when the absolute number of diagnoses during the interruption of the screening programs was  
16 compared with previous periods, an evident reduction was observed. A study performed in  
17 Málaga (Spain) reported that the breast was one of the cancer sites showing a larger decline  
18 in cases in April 2020 compared with April 2019. The authors of that study stated that this  
19 decline could be explained by the interruption of the screening program (30). Similar results  
20 have been found in studies from the Netherlands, Austria, and the United Kingdom (6,7,31).

21 It is still unknown whether the target strategies to reduce the back-log of women who missed  
22 screening due to the pandemic, such as contacting them by telephone calls to schedule an  
23 appointment, will help to detect cancers missed during screening disruption. The possible  
24 influence of the delay on stage at diagnosis needs further evaluation. Although we found no  
25 statistically significant differences between pre- and post-COVID-19 periods in our small  
26 sample, we did find a small 5% increase in cases diagnosed at stage II. Similarly, an  
27 increased risk of late-stage breast cancer was observed in a month-by-month comparison in  
28 Israel in the period following the interruption and restoration of the screening activity (32).  
29 Further investigation on stage at diagnosis is essential, especially considering the potential  
30 increase in interval cancers due to the delay in the planned mammogram schedule. Moreover,  
31 the reduction in participation could increase cancer detection and stage at diagnosis in the  
32 next screening round among women who skipped the post-pandemic round, leaving a span of  
33 four years between consecutive screenings.

34 Our study has some limitations. First, we used pseudo-anonymized data and analyzed each  
35 invitation as an independent measurement, although a single woman can have more than one  
36 invitation. Nevertheless, we considered four groups of type of screening rounds to evaluate  
37 attendance, mitigating the fact that the measurements were not truly independent, although  
38 this study treated them as though they were. Second, the number of cancers detected during  
39 the pandemic period was relatively low, which limited the statistical power of our results.

40 Our study also has some strengths. To our best knowledge, most of the observational  
41 evidence assessing the effect of the pandemic compared screening indicators with the  
42 previous year (33–35). In contrast, we included a long period of four previous rounds (eight

1 years) of invitations for the same target population. We took this longitudinal approach since  
2 it is known that there are fluctuations in participation and cancer detection that may depend  
3 on time (36). Therefore, our approach provides information on the pandemic beyond these  
4 common fluctuations

5 In conclusion, our findings suggest that the impact of the pandemic on screening attendance  
6 depends on the type of screening, with women who regularly participate being the most  
7 affected. Targeting this specific population with a proactive invitation could be a way to  
8 ensure the historically higher participation in this group. Despite this, we should not forget  
9 other groups that attended screening less frequently. Our program has proved to be resilient,  
10 reducing recall and maintaining invitations, false positives, and the cancer detection rate  
11 stable. These results suggest that the roll-out of the program was successful under the  
12 stressful situation provoked by the pandemic. Further prospective research is necessary to  
13 assess whether other factors played a role in participation during the pandemic, as well as to  
14 better characterize the impact of delays on stage at diagnosis and the incidence of interval  
15 cancers.

16

---

17 **Availability of data and materials:** Source data from all tables and figures can be found in  
18 the following Dataset: BOSCH, GUILLERMO, 2022, "Breast cancer screening program  
19 invitations (2012-2021)", <https://doi.org/10.7910/DVN/VVQNWM>, Harvard Dataverse, V1,  
20 UNF:6:CaW3sEp4tMsg13z2I1eZbQ== [fileUNF] Data from "Impact on covid19 dataset  
21 invited women.sav" was used in tables 1 and 2 and figures 1,2 and 3. Data from "cancer  
22 characteristics database.tab" was used in table 3..

23 **Competing interests:** The authors declare that they have no competing interests.

24 **Funding:** This study has received funding by grants from Instituto de Salud Carlos III  
25 FEDER (grant numbers: PI19/00007 and PI21/00058), and by the Health Outcomes-Oriented  
26 Cooperative Research Networks (RICORS) ), with reference RD21/0016/0020 co-funded  
27 with European Union – NextGenerationEU funds.

28 **Authors' contributions:** All authors conceptualized and designed the study. Data was  
29 collected by GB, MP, and FM. GB, JL, and MR performed the statistical analyses. All  
30 authors collaborated in the interpretation of the results. GB, and MP drafted the manuscript.  
31 GB, MP, and FM wrote the final version of the manuscript and revised it critically for  
32 important intellectual content. All authors read and approved the final manuscript.

33 **Acknowledgments:** we would like to thank Cristina Barrufet, Mercè Esturi and Cristina  
34 Hernández in particular for their work and assistance in the performance of this study and the  
35 rest of the team of the PSMAR screening technical office: Isabel Amatriain, Gloria Lagarriga,  
36 Maria Ángeles Mercader, Marina Reyes, Judit Silvilla and Eva Fernández.

37

## 1 **References**

- 2 1. Puricelli Perin DM, Elfström KM, Bulliard JL, Burón A, Campbell C, Flugelman AA,  
3 et al. Early assessment of the first wave of the COVID-19 pandemic on cancer  
4 screening services: The International Cancer Screening Network COVID-19 survey.  
5 *Prev Med (Baltim)*. 2021;151(January):106642.
- 6 2. World Health Organization (WHO). Strengthening the health system response to  
7 COVID-19 Recommendations for the WHO European Region Policy brief.  
8 2020;(April):8. Available from:  
9 <https://www.thelancet.com/journals/langlo/article/PIIS2214-109X>
- 10 3. Peng SM, Yang KC, Chan WP, Wang YW, Lin LJ, Yen AMF, et al. Impact of the  
11 COVID-19 pandemic on a population-based breast cancer screening program. *Cancer*.  
12 2020;126(24):5202–5.
- 13 4. The European Commission’s science and knowledge service. European guidelines on  
14 breast cancer screening and diagnosis | ECIBC. 2020;(39). Available from:  
15 <https://healthcare-quality.jrc.ec.europa.eu/european-breast-cancer-guidelines>
- 16 5. Muratov S, Canelo-Aybar C, Tarride JE, Alonso-Coello P, Dimitrova N, Borisch B, et  
17 al. Monitoring and evaluation of breast cancer screening programmes: Selecting  
18 candidate performance indicators. *BMC Cancer*. 2020;20(1):1–10.
- 19 6. Dinmohamed AG, Cellamare M, Visser O, de Munck L, Elferink MAG, Westenend  
20 PJ, et al. The impact of the temporary suspension of national cancer screening  
21 programmes due to the COVID-19 epidemic on the diagnosis of breast and colorectal  
22 cancer in the Netherlands. *J Hematol Oncol [Internet]*. 2020;13(1):1–4. Available  
23 from: <https://doi.org/10.1186/s13045-020-00984-1>
- 24 7. Tsubulak I, Reiser E, Bogner G, Petru E, Hell-Teutsch J, Reinthaller A, et al. Decrease  
25 in gynecological cancer diagnoses during the COVID-19 pandemic: An Austrian  
26 perspective. *Int J Gynecol Cancer*. 2020;30(11):1667–71.
- 27 8. Mantellini P, Battisti F, Armaroli P, Giubilato P, Ventura L, Zorzi M, et al.  
28 Oncological organized screening programmes in the covid-19 era: An italian survey on  
29 accrued delays, reboot velocity, and diagnostic delay estimates. *Epidemiol Prev*.  
30 2020;44(5–6):344–52.
- 31 9. Yong JHE, Mainprize JG, Yaffe MJ, Ruan Y, Poirier AE, Coldman A, et al. The  
32 impact of episodic screening interruption: COVID-19 and population-based cancer  
33 screening in Canada. *J Med Screen*. 2020;
- 34 10. VANNI G, PELLICCIARO M, MATERAZZO M, BRUNO V, OLDANI C,  
35 PISTOLESE CA, et al. Lockdown of breast cancer screening for COVID-19: Possible  
36 scenario. *In Vivo (Brooklyn)*. 2020;34(5):3047–53.
- 37 11. Gallo V, Chiodini P, Bruzzese D, Kondilis E, Howdon D, Mierau J, et al. Comparing  
38 the COVID-19 pandemic in space and over time in Europe, using numbers of deaths,

- 1 crude rates and adjusted mortality trend ratios. *Sci Rep* [Internet]. 2021;11(1):1–10.  
2 Available from: <https://doi.org/10.1038/s41598-021-95658-4>
- 3 12. Karlinsky A, Kobak D. Tracking excess mortality across countries during the covid-19  
4 pandemic with the world mortality dataset. *Elife*. 2021;10:1–21.
- 5 13. Viguria UA, Casamitjana N. Early interventions and impact of covid-19 in spain. *Int J*  
6 *Environ Res Public Health*. 2021;18(8).
- 7 14. Coronavirus- Cronología de una pandemia en España. [Internet]. *La Vanguardia*. 2021  
8 [cited 2021 Feb 15]. Available from:  
9 [https://stories.lavanguardia.com/ciencia/20210125/33068/coronavirus-cronologia-de-](https://stories.lavanguardia.com/ciencia/20210125/33068/coronavirus-cronologia-de-una-pandemia-en-espana)  
10 [una-pandemia-en-espana](https://stories.lavanguardia.com/ciencia/20210125/33068/coronavirus-cronologia-de-una-pandemia-en-espana)
- 11 15. Maio F, Tari DU, Granata V, Fusco R, Grassi R, Petrillo A, et al. Breast cancer  
12 screening during covid-19 emergency: Patients and department management in a local  
13 experience. *J Pers Med*. 2021;11(5).
- 14 16. Pediconi F, Galati F, Bernardi D, Belli P, Brancato B, Calabrese M, et al. Breast  
15 imaging and cancer diagnosis during the COVID-19 pandemic: recommendations from  
16 the Italian College of Breast Radiologists by SIRM. *Radiol Medica* [Internet].  
17 2020;125(10):926–30. Available from: <https://doi.org/10.1007/s11547-020-01254-3>
- 18 17. Castells X, Sala M, Ascunce N, Salas D, Zubizarreta R, Casamitjana M, et al.  
19 Descripción del cribado del cáncer en España: Proyecto DESCRIC. [Internet].  
20 Informes de Evaluación de Tecnologías Sanitarias, AATRM núm. 2006/01. 2007. 1–  
21 327 p. Available from: [www.msc.es](http://www.msc.es)
- 22 18. Posso M, Alcántara R, Vázquez I, Comerma L, Baré M, Louro J, et al. Mammographic  
23 features of benign breast lesions and risk of subsequent breast cancer in women  
24 attending breast cancer screening. *Eur Radiol*. 2022;32(1):621–9.
- 25 19. Agència de Qualitat i Avaluació Sanitàries de Catalunya. Nou indicador  
26 socioeconòmic del model d'assignació de recursos de l'atenció primària [Internet].  
27 2017. Available from:  
28 [https://catsalut.gencat.cat/web/.content/minisite/catsalut/coneix\\_catsalut/informacio-](https://catsalut.gencat.cat/web/.content/minisite/catsalut/coneix_catsalut/informacio-economica/nou-model-assignacio-recursos-equips-atencio-primaria/Nou_indicador_socioeconomic_AP.pdf)  
29 [economica/nou-model-assignacio-recursos-equips-atencio-](https://catsalut.gencat.cat/web/.content/minisite/catsalut/coneix_catsalut/informacio-economica/nou-model-assignacio-recursos-equips-atencio-primaria/Nou_indicador_socioeconomic_AP.pdf)  
30 [primaria/Nou\\_indicador\\_socioeconomic\\_AP.pdf](https://catsalut.gencat.cat/web/.content/minisite/catsalut/coneix_catsalut/informacio-economica/nou-model-assignacio-recursos-equips-atencio-primaria/Nou_indicador_socioeconomic_AP.pdf)
- 31 20. Giuliano AE, Connolly JL, Edge SB, Mittendorf EA, Rugo HS, Solin LJ, et al. Breast  
32 Cancer-Major changes in the American Joint Committee on Cancer eighth edition  
33 cancer staging manual. *CA Cancer J Clin*. 2017;67(4):290–303.
- 34 21. Román M, Quintana MJ, Ferrer J, Sala M, Castells X. Cumulative risk of breast cancer  
35 screening outcomes according to the presence of previous benign breast disease and  
36 family history of breast cancer: Supporting personalised screening. *Br J Cancer*.  
37 2017;116(11):1480–5.
- 38 22. Kirkegaard P, Edwards A, Andersen B. Balancing risks: Qualitative study of attitudes,

- 1 motivations and intentions about attending for mammography during the COVID-19  
2 pandemic. *Scand J Public Health*. 2021;49(7):700–6.
- 3 23. Rodriguez C, Plasencia A, Schroeder DG. Predictive factors of enrollment and  
4 adherence in a breast cancer screening program in Barcelona (Spain). *Soc Sci Med*.  
5 1995 Apr 1;40(8):1155–60.
- 6 24. Mottram R, Knerr WL, Gallacher D, Fraser H, Khudairy LA-, Ayorinde A, et al.  
7 Factors associated with attendance at screening for breast cancer: a systematic review  
8 and meta- analysis. *BMJ*. 2021;11.
- 9 25. Amram O, Robison J, Amiri S, Pflugeisen B, Roll J, Monsivais P. Socioeconomic and  
10 Racial Inequities in Breast Cancer Screening during the COVID-19 Pandemic in  
11 Washington State. *JAMA Netw Open*. 2021;4(5):2019–22.
- 12 26. Miller MM, Meneveau MO, Rochman CM, Schroen AT, Lattimore CM, Gaspard PA,  
13 et al. Impact of the COVID-19 pandemic on breast cancer screening volumes and  
14 patient screening behaviors. *Breast Cancer Res Treat [Internet]*. 2021;189(1):237–46.  
15 Available from: <https://doi.org/10.1007/s10549-021-06252-1>
- 16 27. Posso M, Comas M, Román M, Domingo L, Louro J, González C, et al. Comorbidities  
17 and Mortality in Patients With COVID-19 Aged 60 Years and Older in a University  
18 Hospital in Spain. *Arch Bronconeumol*. 2020;56(11)(November):756–8.
- 19 28. Manzanares I, Sevilla Guerra S, Lombraña Mencía M, Acar-Denizli N, Miranda  
20 Salmerón J, Martínez Estalella G. Impact of the COVID-19 pandemic on stress,  
21 resilience and depression in health professionals: a cross-sectional study. *Int Nurs Rev*.  
22 2021;(August 2020):1–10.
- 23 29. Haldane V, De Foo C, Abdalla SM, Jung AS, Tan M, Wu S, et al. Health systems  
24 resilience in managing the COVID-19 pandemic: lessons from 28 countries. *Nat Med*  
25 [Internet]. 2021;27(6):964–80. Available from: [http://dx.doi.org/10.1038/s41591-021-](http://dx.doi.org/10.1038/s41591-021-01381-y)  
26 01381-y
- 27 30. Ruiz-Medina S, Gil S, Jimenez B, Rodriguez-Brazzarola P, Diaz-Redondo T, Cazorla  
28 M, et al. Significant decrease in annual cancer diagnoses in Spain during the COVID-19  
29 pandemic: A real-data study. *Cancers (Basel)*. 2021;13(13).
- 30 31. Limb M. Covid-19: Early stage cancer diagnoses fell by third in first lockdown. *BMJ*.  
31 2021;373(May):n1179.
- 32 32. Lloyd MR, Stephens SJ, Hong JC, James TA, Mehta T, Recht A, et al. The impact of  
33 COVID-19 on breast cancer stage at diagnosis. *J Clin Oncol [Internet]*. 2021 May  
34 20;39(15\_suppl):528. Available from:  
35 [https://doi.org/10.1200/JCO.2021.39.15\\_suppl.528](https://doi.org/10.1200/JCO.2021.39.15_suppl.528)
- 36 33. Song H, Bergman A, Chen AT, Ellis D, David G, Friedman AB, et al. Disruptions in  
37 preventive care: Mammograms during the COVID-19 pandemic. *Health Serv Res*.  
38 2020;1–7.

- 1 34. Chen RC, Haynes K, Du S, Barron J, Katz AJ. Association of Cancer Screening  
2 Deficit in the United States with the COVID-19 Pandemic. *JAMA Oncol.*  
3 2021;7(6):878–84.
- 4 35. Toyoda Y, Katanoda K, Ishii K, Yamamoto H, Tabuchi T. Negative impact of the  
5 COVID-19 state of emergency on breast cancer screening participation in Japan.  
6 *Breast Cancer* [Internet]. 2021;28(6):1340–5. Available from:  
7 <https://doi.org/10.1007/s12282-021-01272-7>
- 8 36. Giordano L, Castagno R, Giorgi D, Piccinelli C, Ventura L, Segnan N, et al. Breast  
9 cancer screening in Italy: Evaluating key performance indicators for time trends and  
10 activity volumes. *Epidemiol Prev.* 2015;39(3):30–9.
- 11

1 **Supplementary file 1**

2

3 **Crude logistic-regression models**

4

5 Model 1. Crude participation.

PARTICIPATION (POST-COVID-19)	Estimate	Std. Error	z value	Pr(> z )	odds	OR post/pre	IC- (95%)	IC+ (95%)
	FIRST-TIME INVITEE	-0.14765	0.03226	-4.57	4.71e-06 ***	0.862733019	0.862733019	0.8098203
PREVIOUS NONPARTICIPANT	-2.06799	0.04017	-51.4	< 2e-16 ***	0.12643967	1.08643443	1.00079898	1.178145
REGULAR PARTICIPANT	1.9568	0.02917	67.07	< 2e-16 ***	7.076645528	0.66289973	0.62686327	0.70126568
IRREGULAR PARTICIPANT	-0.67188	0.04779	-14.0	< 2e-16 ***	0.510747469	0.9574072	0.8671546	1.056191

6

7 Model 2. Crude Recall.

RECALL (POST-COVID-19)	Estimate	Std. Error	z value	Pr(> z )	ODDS	OR post/pre	IC-(95%)	IC+(95%)
	PREVALENT SCREENING	-0.10405	0.06385	-1.63	0.103	0.901180237	0.901180237	0.7942011
INCIDENT SCREENING	-1.51211	0.05957	-25.3	<2e-16 ***	0.220444349	0.894956648	0.79856602	1.00038578

8

9 Model 3. Crude false positives.

FALSE POSITIVES (POST-COVID-19)	Estimate	Std. Error	z value	Pr(> z )	ODDS	OR post/pre	IC-(95%)	IC+(95%)
	PREVALENT SCREENING	0.0883	0.07233	1.22	0.222	1.092337	1.09233761	0.94648207
INCIDENT SCREENING	-1.4248	0.07139	-19.95	<2e-16 ***	0.240534	0.94423519	0.82303271	1.0792094

10



1 Model 4. Crude cancer detection.

CANCER DETECTION (POST-COVID-19)								
	<b>Estimate</b>	<b>Std. Error</b>	<b>z value</b>	<b>Pr(&gt; z )</b>	<b>ODDS</b>	<b>OR post/pre</b>	<b>IC-(95%)</b>	<b>IC+(95%)</b>
PREVALENT SCREENING	-0.08015	0.28029	-0.286	0.775	0.922977	0.922977	0.515085	1.55732
INCIDENT SCREENING	-0.24311	0.18435	-1.319	0.187	0.784185	0.893820	0.661616	1.18544

2